Get the Stockscreener App
0.7928
0.88%
0.0069
Lexaria Bioscience Corp stock is traded at $0.7928, with a volume of 151.54K.
It is up +0.88% in the last 24 hours and down -18.27% over the past month.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
See More
Previous Close:
$0.7859
Open:
$0.78
24h Volume:
151.54K
Relative Volume:
1.08
Market Cap:
$15.51M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.8018
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
-3.26%
1M Performance:
-18.27%
6M Performance:
-45.32%
1Y Performance:
-73.83%
1-Day Range:
$0.7749
$0.82
1-Week Range:
$0.7749
$0.877
52-Week Range:
$0.7749
$4.38
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.7928 | 16.36M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Will Lexaria Bioscience Corp. Equity Warrant benefit from macro trends2025 Geopolitical Influence & Reliable Volume Spike Alerts - Newser
Chartists See Breakout Potential in Lexaria Bioscience Corp.Weekly Profit Report & Community Verified Watchlist Alerts - newsyoung.net
Pattern recognition hints at Lexaria Bioscience Corp. upsideJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
How to build a custom watchlist for Lexaria Bioscience Corp.July 2025 Gainers & Weekly Return Optimization Alerts - Newser
Will Lexaria Bioscience Corp. benefit from macro trendsMarket Risk Summary & Technical Buy Zone Confirmations - Newser
Technical signs of recovery in Lexaria Bioscience Corp.Quarterly Performance Summary & Reliable Price Breakout Signals - Newser
Price action breakdown for Lexaria Bioscience Corp.2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
Has Lexaria Bioscience Corp. Equity Warrant formed a bullish divergenceRate Hike & Free Community Supported Trade Ideas - Newser
Using Bollinger Bands to evaluate Lexaria Bioscience Corp.Buy Signal & Safe Capital Growth Plans - Newser
Will Lexaria Bioscience Corp. price bounce be sustainableDay Trade & Capital Efficiency Focused Strategies - Newser
What recovery options are there for Lexaria Bioscience Corp.Market Performance Summary & Community Consensus Picks - Newser
What earnings revisions data tells us about Lexaria Bioscience Corp. Equity Warrant2025 Short Interest & Growth Focused Entry Point Reports - Newser
Regression analysis insights on Lexaria Bioscience Corp. Equity Warrant performanceJuly 2025 Volume & AI Optimized Trade Strategies - Newser
Can Lexaria Bioscience Corp. rally from current levels2025 Trading Volume Trends & AI Driven Stock Reports - Newser
Price momentum metrics for Lexaria Bioscience Corp. Equity Warrant explainedTrade Ideas & Verified Chart Pattern Trade Signals - Newser
Lexaria Bioscience Corp. Equity Warrant stock volume spike explained2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
Comparing Lexaria Bioscience Corp. in custom built stock radarsJuly 2025 Macro Moves & Community Supported Trade Ideas - Newser
What’s the recovery path for long term holders of Lexaria Bioscience Corp. Equity WarrantEarnings Overview Summary & Risk Managed Trade Strategies - Newser
Heatmap analysis for Lexaria Bioscience Corp. and competitorsMarket Movement Recap & Daily Chart Pattern Signal Reports - Newser
Risk adjusted return profile for Lexaria Bioscience Corp. analyzedPortfolio Return Report & Growth-Oriented Investment Plans - Newser
Multi factor analysis applied to Lexaria Bioscience Corp. Equity WarrantWeekly Stock Summary & Weekly Market Pulse Alerts - Newser
Lexaria Bioscience Corp. Equity Warrant recovery potential after sell offEarnings Beat & Low Risk Entry Point Guides - Newser
Will Lexaria Bioscience Corp. Equity Warrant bounce back from current support2025 Key Lessons & Free Verified High Yield Trade Plans - Newser
Is Lexaria Bioscience Corp. Equity Warrant showing signs of accumulation2025 Market Outlook & Fast Exit and Entry Strategy Plans - Newser
Forecasting Lexaria Bioscience Corp. price range with options data2025 Volatility Report & Weekly High Momentum Picks - Newser
Will Lexaria Bioscience Corp. continue its uptrend2025 Market Overview & Precise Buy Zone Tips - Newser
What MACD and RSI say about Lexaria Bioscience Corp.2025 Institutional Moves & Consistent Profit Trade Alerts - Newser
Is it too late to sell Lexaria Bioscience Corp. Equity WarrantJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
Lexaria Bioscience Completes Key Phase 1b Study Milestone - MSN
What to expect from Lexaria Bioscience Corp. Equity Warrant in the next 30 daysRisk Management & Expert Approved Momentum Trade Ideas - Newser
Will earnings trigger a reversal in Lexaria Bioscience Corp. Equity WarrantTrade Volume Report & Smart Allocation Stock Reports - Newser
Chart based analysis of Lexaria Bioscience Corp. Equity Warrant trendsMarket Risk Report & Reliable Entry Point Trade Alerts - Newser
What Fibonacci levels say about Lexaria Bioscience Corp. reboundWeekly Market Report & AI Optimized Trade Strategies - Newser
Using data models to predict Lexaria Bioscience Corp. stock movementJuly 2025 Catalysts & Long-Term Capital Growth Strategies - Newser
Can Lexaria Bioscience Corp. be recession proof2025 Support & Resistance & Reliable Volume Spike Alerts - mustnews.co.kr
Why Lexaria Bioscience Corp. Equity Warrant stock attracts strong analyst attentionWeekly Loss Report & Verified Momentum Stock Ideas - Newser
How Lexaria Bioscience Corp. stock performs during market volatility2025 Market Outlook & Advanced Technical Signal Analysis - newsimpact.co.kr
How to read the order book for Lexaria Bioscience Corp.Weekly Investment Report & Verified Entry Point Signals - Newser
Lexaria Bioscience's DehydraTECH Platform: A Disruptive Force in GLP-1 Oral Delivery - AInvest
Lexaria Bioscience Completes Last Patient, Last Visit in Phase 1b GLP-1 Study, Awaits Laboratory Analysis - AInvest
Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study - Yahoo Finance
What MACD and RSI say about Lexaria Bioscience Corp. Equity WarrantGlobal Markets & AI Enhanced Trading Alerts - Newser
Lexaria Bioscience Corp. Equity Warrant Stock Support and Resistance Levels You Should KnowJuly 2025 Outlook & Technical Pattern Alert System - Newser
Risk vs reward if holding onto Lexaria Bioscience Corp.Earnings Miss & Stock Portfolio Risk Management - Newser
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexaria Bioscience Corp Stock (LEXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BUNKA CHRISTOPHER | Director |
Jul 30 '25 |
Buy |
0.91 |
11,900 |
10,866 |
281,912 |
| McKechnie William Edward | Director |
Jul 29 '25 |
Buy |
0.91 |
5,000 |
4,532 |
18,191 |
| DOCHERTY JOHN MARTIN | President & CSO |
Jul 29 '25 |
Buy |
0.93 |
5,376 |
4,989 |
5,376 |
| Carle Vanessa | Secretary |
Jul 29 '25 |
Buy |
0.91 |
750 |
682 |
750 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Jul 29 '25 |
Buy |
0.91 |
15,000 |
13,641 |
65,000 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 03 '24 |
Buy |
2.47 |
27,172 |
67,175 |
50,000 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 02 '24 |
Buy |
2.24 |
22,828 |
51,217 |
22,828 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):